// App-Quantinova.ai

164 : A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Researchers

Presenter

  • Erica Brivio

Principal Investigators

  • Adriana Thano

  • Arnaud Petit

  • Britta Julia Vormoor

  • Susana Rives

  • Bella Bielorai

  • Claudia Rossig

  • Carmelo Rizzari

  • Vincent H.J. Van Der Velden

  • Anneke C.J. Ammerlaan

  • Monique L. Den Boer

  • Barbara Sleight

  • Gernot Engstler

  • Jan Stary

  • Francisco Jos Bautista Sirvent

  • Christiane Chen-Santel

  • Bndicte Bruno

  • Yves Bertrand

  • Fanny Rialland

  • Genevive Plat

  • Dirk Reinhardt

  • Luciana Vinti

  • Arend von Stackelberg

  • Christian Michel Zwaan

Medical Centers

  • Princess Maxima Center for Pediatric Oncology, Netherlands

  • Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands

  • Department of Pediatric Hematology and Oncology,IRCCS Bambino Gesù Children's Hospital, Sapienza University of Rome,Rome,Italie

  • Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, NLD

  • department of pediatric Hematology and Oncology, Hopital Armand Trousseau, APHP, Sorbonne Université, Paris, France

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht, Netherlands

  • Pediatric Oncology and Hematology Department, Hospital Sant Joan de Déu de Barcelona, Barcelona, ESP

  • Division of Pediatric Hematology and Oncology, Sheba Medical Center, Ramat-Gan, ISR

  • Pediatric Hematology and Oncology, University Hospital, Muenster, Germany

  • Pediatric Hematology-Oncology Unit, MBBM Foundation, ASST Monza, University of Milano-Bicocca, Monza, Italy

  • Department of Immunology, Erasmus University Medical Center, Rotterdam, NLD

  • PHARMO Institute, Utrecht, Netherlands

  • Pfizer, Groton, CT

  • St Anna Childrens Hospital, Medical University of Vienna, Vienna, Austria

  • Department of Paediatric Haematology and Oncology, Charles University 2nd Medical School, Prague, Czech Republic

  • Pediatric Oncology and hematology Department, Hospital Niño Jesus, Madrid, Spain

  • Medical Department, Division of Oncology and Hematology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Department of Pediatrics, University Medical Centre, Rostock, Rostock, Germany

  • Pediatric Hematology, Hospital Jeanne de Flandre, Lille, France

  • Institute of Pediatric Hematology and Oncology, Civil Hospital of Lyon, Claude Bernard University, Lyon, France

  • Service Onco-Hématologie Pédiatrique, Hôpital Mère-Enfant, Nantes University Hospital, Nantes, France

  • Service d’Hématologie-Immunologie-Oncologie, Hôpital des Enfants, CHU Toulouse, Toulouse, France

  • Department of Pediatric Oncology and Hematology, Essen University Hospital, Essen, Germany

  • Department of Pediatric Haematology and Oncology and Cell and Gene Therapy,IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza, University of Rome,Rome,Italie

  • IntReALL study group, Berlin, Germany

Locations

  • Netherlands

  • Italy

  • France

  • Germany

  • United States

  • Austria

  • Czech Republic

  • Spain

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N-Acylethanolamine acid amidase

Drug/Treatment

  • Inotuzumab ozogamicin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Pfizer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved